Global Migraine Treatment Market Size study, by Types (Episodic, Migraine with Aura, Chronic and Others), by Treatment (Acute/Abortive Treatment, Preventive/Prophylactic Treatment, Non-Pharmacological Therapies and Devices), by Product Type (Prescription

Global Migraine Treatment Market Size study, by Types (Episodic, Migraine with Aura, Chronic and Others), by Treatment (Acute/Abortive Treatment, Preventive/Prophylactic Treatment, Non-Pharmacological Therapies and Devices), by Product Type (Prescription and Over the Counter), by End-User (Hospitals, Clinics, Homecare, Others) and Regional Forecasts 2022-2028

Global Migraine Treatment Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. A migraine is a headache that causes severe throbbing pain or a pulsing sensation, usually on one side of the head. Rising awareness regarding migraine, growing prevalence of migraine and new treatment launches for migraine are the major factors driving the growth of the market. Such as, in August 2020, Eversana partnered with Zosano Pharma Corp. for the distribution and commercialization of Qtrypta, in the United States. Qtrypta is a transdermal migraine treatment candidate. Also, in May 2021, Impel NeuroPharma launched Reroute Migraine Relief, an educational initiative aimed at raising awareness of the complexities of migraine, including the underrecognized connection between the brain and gut. Furthermore, approval for new migraine treatments coupled with research and development activities taking place for migraine treatment are the factors expected to inject growth in the coming years. In September 2021, U.S. Food and Drug Administration (FDA) awarded approval to QULIPTA, the preventive treatment of episodic migraine in adults. However, presence of alternative therapies such as homeopathy and limitations of current therapies may impede the growth in the near future.

The key regions considered for the Global Migraine Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is leading the global market in terms of revenue owing to the presence of established players and rising prevalence of migraine. Whereas, Asia Pacific is expected to grow with the highest growth rate in coming years, owing to research and development activities happening in the region coupled with rising healthcare expenditure.

Major market players included in this report are:
Pfizer Inc.
Eli Lilly and Company
Amgen Inc.
GlaxoSmithKline plc.
Novartis AG
Bayer AG
Allergan
Abbott
Allodynic Therapeutics, LLC
AOBiome
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Treatment offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Types:
Episodic
Migraine with Aura
Chronic
Others
By Treatment:
Acute/Abortive Treatment
Preventive/prophylactic Treatment
Non-Pharmacological Therapies and Devices
By Product Type:
Prescription
Over The Counter
By End-User:
Hospitals
Clinics
Homecare
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Migraine Treatment Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors


Companies Mentioned

Pfizer Inc.
Eli Lilly and Company
Amgen Inc.
GlaxoSmithKline plc.
Novartis AG
Bayer AG
Allergan
Abbott
Allodynic Therapeutics, LLC
AOBiome

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.